Search

A recent study on neurofibromatosis type 1 (NF1) from Puducherry, India, highlights the importance of ocular examination in diagnosing the condition. NF1 is a common genetic disorder inherited in an autosomal dominant manner. Dermatologic manifestations, such as cafe-au-lait macules and freckles, are typically present in NF1 individuals, while neurofibromas may appear later in adulthood. The study emphasizes the value of genetic analysis in diagnosing NF1, especially in children without cutaneous neurofibromas. The presence of Lisch nodules, which occur by around 7 years of age, can help differentiate NF1 from other conditions. The case report underscores the significance of ophthalmic evaluation in all NF1 cases, particularly in resource-poor settings where genetic studies may not be feasible. [Extracted from the article]

A recent study conducted by researchers at COMSATS University Islamabad in Pakistan has utilized bioinformatics to explore the pathways involved in Neurofibromatosis Type 1 (NF1), a benign tumor predisposition syndrome. The study identified 10 hub genes out of 1730 differentially expressed genes (DEGs) associated with NF1. Additionally, three specific genes (BRCA1, KIF11, and LAMA1) were found to be altered in NF1 patients and may serve as potential drug targets. The research also identified 13 potential drugs that could be effective against NF1. This study provides valuable insights into the pathogenesis of NF1 and offers potential avenues for further research and treatment development. [Extracted from the article]

Researchers at the Van Andel Research Institute in Grand Rapids, Michigan have developed a patient-derived explant (PDE) ex vivo culture model for cutaneous neurofibromas (CNFs), which are benign tumors that occur in individuals with neurofibromatosis type 1. This model allows for the study of CNFs and the testing of potential drugs. The researchers found that proliferation of CNFs was associated with increased T-cell infiltration and identified inflammatory signaling pathways in the tumors. Glucocorticoid treatment was shown to reduce the expression of proinflammatory genes in the model. This research provides a useful tool for further mechanistic studies and preclinical drug testing for neurofibromatosis type 1-related cutaneous neurofibromas. [Extracted from the article]

Researchers from the Centro Hospitalar Universitario de Sao Joao have published a new report on neurofibromatosis type 1 (NF1), a genetic disorder characterized by various neurocutaneous manifestations. The report focuses on a case study of a seven-year-old boy with suspected NF1 who exhibited typical features such as cafe-au-lait spots and neurofibromas, as well as attention-deficit hyperactivity disorder and developmental delay. Genetic testing revealed an Alu insertion variant within the NF1 gene and a 16p13.11 duplication, highlighting the complexity of NF1 and the importance of considering coexisting genetic disorders. The findings contribute to the precision of diagnosis, prognosis, and genetic counseling for NF1 patients. [Extracted from the article]

A new report from the University of Iowa discusses research findings on neurofibromatosis type 1 (NF1), a common neurogenetic disorder that affects brain function. NF1 affects approximately 1 in 3,000 individuals worldwide and has a range of clinical manifestations. The report highlights the progress made in understanding the disorder's pathophysiology, particularly in relation to alterations in neuronal function and metabolism. The researchers emphasize the need for further investigation into the complex signaling and systemic interactions involved in NF1. [Extracted from the article]

A recent study conducted by investigators at the University of Exeter in the United Kingdom has identified a potential new treatment for neurofibromatosis type 1 (NF1) tumors. NF1 is a genetic disorder characterized by the formation of benign tumors called neurofibromas within nerves. The researchers discovered that inhibiting the autophagy pathway, specifically using the drug chloroquine (CQ), showed promise in selectively killing NF1-deficient cells. This finding suggests that targeting the autophagy pathway could be a promising approach for treating NF1-associated tumors. [Extracted from the article]

A recent report from the Ann and Robert H. Lurie Children's Hospital of Chicago discusses the findings of a study on Neurofibromatosis Type 1 (NF-1) microdeletion syndrome. The study aimed to expand the understanding of this syndrome and its natural history. The researchers conducted a retrospective chart review of 57 individuals with NF-1 microdeletion syndrome and found that many of them had facial features, plexiform neurofibromas, and malignant peripheral nerve sheath tumors. Neurodevelopmental manifestations were also observed, including developmental delays, speech delays, learning difficulties, and attention-deficit/hyperactivity disorder. The study concluded that neurocognitive outcomes in adults with NF-1 microdeletion syndrome varied more than typically reported. [Extracted from the article]

This article discusses a research report on neurofibromatosis type 1 (NF1), a genetic disorder that causes nerve tumors. The report focuses on a compound called benzamide, which has shown potential in inhibiting tumor growth. The research highlights the role of enzymes and coenzymes in the development of these tumors. This information is valuable for individuals interested in neurodegenerative diseases, neurocutaneous syndromes, and neuromuscular diseases. [Extracted from the article]

A recent narrative review conducted by researchers at Temple University explores the impact of chronic pain on the quality of life of individuals with Neurofibromatosis Type 1 (NF1). The review highlights that chronic pain in NF1 is diverse and can negatively affect various aspects of a person's life, including pain interference, depression, anxiety, and cognitive functioning. The study also discusses potential interventions, such as pharmacological agents and mind-body interventions, that show promise in managing pain and improving quality of life for individuals with NF1. However, further research is needed to validate the effectiveness of these interventions. [Extracted from the article]

A study conducted by three large European preimplantation genetic testing (PGT) centers has examined the technical challenges and pitfalls of PGT for neurofibromatosis type 1 (NF1). NF1 is a neurocutaneous disorder with high mutation rates and extreme clinical variability. The study found that the high mutation rate and presence of germline mosaicism, particularly in cases of deletions, pose difficulties in counseling, test development, and PGT treatment. The findings of this study could improve reproductive counseling for NF1 patients and aid in test development for other autosomal dominant PGT indications with similar characteristics. [Extracted from the article]

A recent study conducted by researchers at the University of Wisconsin examined the feasibility and acceptability of a telehealth intervention called PEERS(R) for adolescents with neurofibromatosis type 1 (NF1) and their caregivers. NF1 is a condition that often leads to social difficulties in children and adolescents. The study found that the telehealth intervention was well-received, with low dropout rates and high attendance. Caregivers found sessions related to everyday interactions most helpful, while adolescents found sessions related to social nuances and get-togethers most helpful. Overall, the study supports the use of telehealth interventions for improving peer relationships in adolescents with NF1. [Extracted from the article]

A recent study conducted at Children's University Hospital Nino Jesus in Madrid, Spain, has provided new insights into neurofibromatosis type 1 (NF1). The study focused on the use of selumetinib, an oral selective inhibitor, for the treatment of symptomatic, inoperable plexiform neurofibromas (PNs) in NF1 patients. The results showed that selumetinib was associated with clinical and radiological response, and the drug was well-tolerated with no significant toxicities reported. This study highlights the potential of selumetinib as a treatment option for NF1 patients with PNs. [Extracted from the article]

A recent study conducted at Bezmialem Vakif University in Istanbul, Turkey, explored the presence of auditory pathway abnormalities in children with neurofibromatosis type 1 (NF1) who had brainstem focal areas of abnormal signal intensity (FASI). The researchers used diffusion tensor imaging (DTI) to compare mean diffusivity (MD) and fractional anisotropy (FA) values in the auditory pathways of NF1 patients with and without FASI, as well as healthy controls. The study found that NF1 patients with brainstem FASI had altered neuronal integrity in the auditory pathways, and these changes may regress with age. Further research is needed to understand the implications of these findings for NF1 patients. [Extracted from the article]

A recent report from Massachusetts General Hospital discusses the findings of a study on Neurofibromatosis Type 1 (NF1), a rare autosomal dominant disorder characterized by the proliferation of cells from neural crest origin. The study focuses on ocular manifestations of NF1, specifically "choroidal abnormalities" that can be detected using near-infrared ocular coherence tomography imaging. The researchers found that these abnormalities are associated with multifocal choroidal melanocytic clusters, consistent with choroidal melanocytic hamartomas. The study concludes that while both choroidal abnormalities and Lisch nodules are melanocytic hamartomas, there are clear phenotypical differences in their morphologies. [Extracted from the article]

Researchers at the University of Maryland Medical Center Midtown Campus have published a new study on neurofibromatosis type 1 (NF1). The study focuses on a case of metastatic pheochromocytoma to the bones in a patient with NF1, eight years after the initial surgery to remove the primary tumors. The researchers highlight the challenges in predicting malignant disease in patients with primary tumors without metastases and recommend annual biochemical testing and lifelong follow-up for patients with a genetic predisposition. The study provides valuable insights into the management and follow-up of patients with NF1 and pheochromocytoma. [Extracted from the article]

Researchers from Golestan University of Medical Sciences in Iran have conducted a study to translate and examine the psychometrics of the Persian version of the Neurofibromatosis Type 1 Adult Health-related Quality of Life (NF1-AdQOL) questionnaire. The study involved 414 adult patients with neurofibromatosis type 1, and validity and reliability were assessed using various methods. The findings showed that the Persian version of the questionnaire is a reliable and valid instrument for measuring the quality of life of patients with neurofibromatosis type 1. This research provides valuable insights into the assessment of quality of life in this patient population. [Extracted from the article]

A recent pilot study conducted by the University of Wisconsin examined the effectiveness of a telehealth intervention called PEERS(R) in improving peer relationships for adolescents with neurofibromatosis type 1 (NF1). The study found that the intervention showed significant improvement in social outcomes, including social-emotional skills, social impairment, the number of adolescent get-togethers, and teen social knowledge. The researchers concluded that the PEERS(R) intervention holds promise in supporting the social and friendship skills of adolescents with NF1 who experience social difficulties. This study provides valuable insights into interventions for social difficulties in the NF1 population. [Extracted from the article]

A recent study conducted by researchers at the National University of Singapore focused on neurofibromatosis type 1 (NF1), a genetic condition that predisposes individuals to tumors. The study aimed to review the diagnostic modalities and strategies used for assessing complications in adult patients with NF1. The researchers found that there is robust data on diagnostic modalities in high-income countries, but a lack of data in low- and middle-income countries. They concluded that efforts should be made to publish data from low- and middle-income countries to develop clinical practice guidelines that are relevant to local contexts. [Extracted from the article]

A recent study conducted by researchers at the Universidad de Leon examined the impact of neurofibromatosis type 1 (NF1) on the quality of life (QoL) of affected patients. NF1 is a common condition that can lead to melanin lesions and benign tumors, causing both aesthetic and functional burdens. The study found that NF1 significantly affects the psychological well-being of patients, with female and low-educated patients being at higher risk of depression. Additionally, symptoms such as itching and sleep troubles were identified as negatively impacting the QoL of NF1 patients. This research provides valuable insights into the experiences of individuals living with NF1 and highlights the importance of addressing their specific needs. [Extracted from the article]

A recent study conducted by researchers at Capital Medical University in Beijing, China, explored the safety and effectiveness of using halo gravity traction (HGT) combined with traditional growing rods (TGRs) in the treatment of severe early-onset scoliosis (EOS) with neurofibromatosis type 1 (NF-1). The study involved 15 children diagnosed with NF-1 EOS who underwent HGT before growing rod implantation. The results showed that HGT combined with TGRs was well-tolerated and effective in correcting spinal deformities, restoring trunk balance, and increasing spinal height. The study concluded that this treatment approach could be a viable option for managing severe NF-1 EOS with few complications. [Extracted from the article]

A recent study conducted by the National Cancer Institute (NCI) aimed to assess the transition readiness of adolescents and young adults (AYAs) with neurofibromatosis type 1 (NF1) and plexiform neurofibromas. The study found that AYAs with NF1 expressed confidence in many areas of transition readiness but still required support, particularly with self-management skills. The findings suggest that early assessment, psychoeducation, and support for transition readiness to adult care would benefit AYAs with NF1. The study highlights the importance of addressing the gaps in understanding future health risks for this population. [Extracted from the article]

Researchers from the Germans Trias i Pujol Research Institute have made progress in exploring potential treatments for skin tumors associated with neurofibromatosis type 1. Neurofibromatosis type 1 is a rare genetic disorder that leads to the development of skin tumors called cutaneous neurofibromas. Current treatment involves monitoring the tumors and surgically removing them if necessary, but this is only a partial solution as the tumors can grow back. However, recent research has uncovered a potential breakthrough in addressing these skin growths. By disrupting the balance of two critical cellular pathways, a combination therapy involving the drugs Selumetinib and Ogerin has shown promising results in halting the expansion of Schwann cells, which are responsible for tumor growth. This could potentially shift the current treatment paradigm for neurofibromatosis type 1 skin tumors from surgery to a more targeted pharmaceutical approach. [Extracted from the article]

A recent report from the Department of Neurosciences discusses a case of a 4-year-old girl with neurofibromatosis type 1 who developed paronychia, a nail infection, as a result of selumetinib therapy. The researchers conducted histopathological studies on the inflamed skin around the nails to understand the impact of selumetinib therapy. They found that the cutaneous reaction was consistent with other medications and suggested a non-specific immune activation as the underlying mechanism. The girl underwent nail surgery and resumed selumetinib treatment without experiencing a recurrence of paronychia during a 3-month follow-up period. [Extracted from the article]

A new study conducted at Eppendorf University Hospital explores the impact of facial plexiform neurofibroma (FPNF) on the symmetry of the mandible in patients with neurofibromatosis type 1 (NF1). The study found that FPNF patients often exhibit significant deviations in mandibular symmetry compared to patients with disseminated cutaneous neurofibroma (DNF) and control subjects without NF1. These findings suggest that characteristic patterns of mandibular deformity can be measured on radiographs and may serve as initial indicators of NF1. The study also highlights the importance of considering tumor-associated alterations of the mandible in surgical planning for NF1 patients. [Extracted from the article]

A recent report discusses research findings on neurofibromatosis type 1 (NF1), a genetic disorder that affects 1 in 3000 individuals. The study focused on the ocular manifestations of NF1 and evaluated complications in 30 eyes of 15 NF1 cases. The most common ocular presentation was Lisch nodules, and other manifestations included ectropion uveae, optic nerve glioma, and closed angles with raised intraocular pressure. The research emphasizes the importance of regular ocular examination and follow-up for NF1 patients. The full report can be accessed through the Kerala Journal of Ophthalmology. [Extracted from the article]

This article discusses a study on the relationship between early-life immune activation and the development of epilepsy in individuals with Neurofibromatosis type 1 (NF1), a common neurocutaneous disorder. The study used a mouse model of NF1 and found that early-life immune activation promoted spontaneous seizure activity in adulthood only in mice with NF1. However, there was no effect on spatial learning and memory. The findings suggest that early-life immune activation may be a risk factor for NF1-associated epilepsy. [Extracted from the article]

Keywords: Chicago; State:Illinois; United States; North and Central America; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Chicago State:Illinois United States North and Central America Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1078 1078 1 10/24/23 20231023 NES 231023 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- A new study on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 is now available. Chicago, State:Illinois, United States, North and Central America, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Angiology, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Superficial Temporal Artery Keywords: Angiology; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Superficial Temporal Artery EN Angiology Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Superficial Temporal Artery 730 730 1 10/16/23 20231020 NES 231020 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Data detailed on neurofibromatosis type 1 have been presented. [Extracted from the article]

Genetics, Health and Medicine, Nerve Sheath Neoplasms, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibroma, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Peripheral Nervous System Neoplasms Keywords: Genetics; Health and Medicine; Nerve Sheath Neoplasms; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibroma; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Peripheral Nervous System Neoplasms EN Genetics Health and Medicine Nerve Sheath Neoplasms Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibroma Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Peripheral Nervous System Neoplasms 1173 1173 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on neurofibromatosis type 1. [Extracted from the article]

Anesthesia, Cancer, Endocrinology, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Oncology, Pain Medicine, Peripheral Nervous System Diseases and Conditions, Pheochromocytoma Keywords: Anesthesia; Cancer; Endocrinology; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Oncology; Pain Medicine; Peripheral Nervous System Diseases and Conditions; Pheochromocytoma EN Anesthesia Cancer Endocrinology Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Oncology Pain Medicine Peripheral Nervous System Diseases and Conditions Pheochromocytoma 1318 1318 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators discuss new findings in neurofibromatosis type 1. [Extracted from the article]

Health and Medicine, Medical Records, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Records as Topic Keywords: Health and Medicine; Medical Records; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Records as Topic EN Health and Medicine Medical Records Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Records as Topic 957 957 1 10/03/23 20231006 NES 231006 2023 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New research on neurofibromatosis type 1 is the subject of a new report. [Extracted from the article]

Keywords: Asia; Health and Medicine; Imaging Technology; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Optical Coherence Tomography; Pediatrics; Peripheral Nervous System Diseases and Conditions; Technology EN Asia Health and Medicine Imaging Technology Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Optical Coherence Tomography Pediatrics Peripheral Nervous System Diseases and Conditions Technology 646 646 1 09/19/23 20230923 NES 230923 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on neurofibromatosis type 1. Asia, Health and Medicine, Imaging Technology, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Optical Coherence Tomography, Pediatrics, Peripheral Nervous System Diseases and Conditions, Technology. [Extracted from the article]

Diagnostics and Screening, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Diagnostics and Screening; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Diagnostics and Screening Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 631 631 1 09/19/23 20230923 NES 230923 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New research on neurofibromatosis type 1 is the subject of a new report. Keywords for this news article include: Sapienza University of Rome, Rome, Italy, Europe, Neurofibromatoses, Health and Medicine, Neurocutaneous Syndromes, Neurofibromatosis Type 1, Diagnostics and Screening, Neuromuscular Diseases and Conditions, Neurodegenerative Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Keywords for this news article include: Irvine, California, United States, North and Central America, Health and Medicine, Nerve Sheath Neoplasms, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibroma, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Peripheral Nervous System Neoplasms, University of California Irvine. Keywords: Irvine; State:California; United States; North and Central America; Health and Medicine; Nerve Sheath Neoplasms; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibroma; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Peripheral Nervous System Neoplasms EN Irvine State:California United States North and Central America Health and Medicine Nerve Sheath Neoplasms Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibroma Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Peripheral Nervous System Neoplasms 410 410 1 09/19/23 20230923 NES 230923 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- A new study on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 is now available. [Extracted from the article]

Lagarto, Brazil, South America, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Lagarto; Brazil; South America; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Lagarto Brazil South America Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 433 433 1 09/19/23 20230923 NES 230923 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Fresh data on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 are presented in a new report. [Extracted from the article]

Keywords: Diagnostics and Screening; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Diagnostics and Screening Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 454 454 1 09/04/23 20230908 NES 230908 2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Research findings on neurofibromatosis type 1 are discussed in a new report. Diagnostics and Screening, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Philadelphia, State:Pennsylvania, United States, North and Central America, Health and Medicine, Nerve Sheath Neoplasms, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibroma, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Peripheral Nervous System Neoplasms, Plexiform Neurofibroma Keywords: Philadelphia; State:Pennsylvania; United States; North and Central America; Health and Medicine; Nerve Sheath Neoplasms; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibroma; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Peripheral Nervous System Neoplasms; Plexiform Neurofibroma EN Philadelphia State:Pennsylvania United States North and Central America Health and Medicine Nerve Sheath Neoplasms Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibroma Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Peripheral Nervous System Neoplasms Plexiform Neurofibroma 176 176 1 09/04/23 20230908 NES 230908 2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- A new study on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 is now available. [Extracted from the article]

Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 782 782 1 08/21/23 20230825 NES 230825 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on neurofibromatosis type 1. [Extracted from the article]

Dialysis, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Dialysis; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Dialysis Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 624 624 1 07/31/23 20230804 NES 230804 2023 JUL 31 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Fresh data on neurofibromatosis type 1 are presented in a new report. Keywords for this news article include: Renaissance School of Medicine at Stony Brook University, Dialysis, Neurofibromatoses, Health and Medicine, Neurocutaneous Syndromes, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Neurodegenerative Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Pediatrics, Peripheral Nervous System Diseases and Conditions, Therapy Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Pediatrics; Peripheral Nervous System Diseases and Conditions; Therapy EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Pediatrics Peripheral Nervous System Diseases and Conditions Therapy 686 686 1 07/24/23 20230728 NES 230728 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on neurofibromatosis type 1. [Extracted from the article]

Keywords: Cancer; Endocrine Research; Endocrinology; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Oncology; Peripheral Nervous System Diseases and Conditions; Pheochromocytoma EN Cancer Endocrine Research Endocrinology Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Oncology Peripheral Nervous System Diseases and Conditions Pheochromocytoma 1062 1062 1 07/03/23 20230703 NES 230703 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Current study results on neurofibromatosis type 1 have been published. Cancer, Endocrine Research, Endocrinology, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Oncology, Peripheral Nervous System Diseases and Conditions, Pheochromocytoma. [Extracted from the article]

Keywords: Hamburg; Germany; Europe; Health and Medicine; Nerve Sheath Neoplasms; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibroma; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Peripheral Nervous System Neoplasms EN Hamburg Germany Europe Health and Medicine Nerve Sheath Neoplasms Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibroma Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Peripheral Nervous System Neoplasms 824 824 1 07/03/23 20230703 NES 230703 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Data detailed on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 have been presented. Hamburg, Germany, Europe, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibroma, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Nerve Sheath Neoplasms, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Peripheral Nervous System Neoplasms. [Extracted from the article]

Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1012 1012 1 06/05/23 20230609 NES 230609 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Current study results on neurofibromatosis type 1 have been published. Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 118 118 1 06/05/23 20230609 NES 230609 2023 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on neurofibromatosis type 1. [Extracted from the article]

Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Pediatrics; Peripheral Nervous System Diseases and Conditions EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Pediatrics Peripheral Nervous System Diseases and Conditions 599 599 1 05/29/23 20230602 NES 230602 2023 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Fresh data on neurofibromatosis type 1 are presented in a new report. Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Pediatrics, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 799 799 1 05/02/23 20230505 NES 230505 2023 MAY 5 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on neurofibromatosis type 1. Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Neurofibromatosis Type 1. [Extracted from the article]

New York City, State:New York, United States, North and Central America, Bone Diseases and Conditions, Health and Medicine, Hospitals, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Orthopedics, Peripheral Nervous System Diseases and Conditions, Risk and Prevention, Scoliosis, Spinal Curvatures, Spinal Diseases and Conditions, Surgery Keywords for this news article include: New York City, New York, United States, North and Central America, Bone Diseases and Conditions, Health and Medicine, Hospitals, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Orthopedics, Peripheral Nervous System Diseases and Conditions, Risk and Prevention, Scoliosis, Spinal Curvatures, Spinal Diseases and Conditions, Surgery, Icahn School of Medicine at Mount Sinai. [Extracted from the article]